192,593 Cencora, Inc. $COR Shares Sold by Voya Investment Management LLC

Cencora logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Voya Investment Management cut its Cencora stake by 67.5% in the third quarter, selling 192,593 shares and retaining 92,776 shares valued at about $27.9 million.
  • Cencora reported quarterly EPS of $4.66, above the $4.58 consensus, and revenue of $88.35 billion, also topping estimates; revenue rose 5.5% year over year.
  • The company raised its quarterly dividend from $0.60 to $0.66 per share. Analysts’ consensus rating was “Moderate Buy,” with an average price target of $381.
  • Interested in Cencora? Here are five stocks we like better.

Voya Investment Management LLC lowered its stake in Cencora, Inc. (NYSE:COR - Free Report) by 67.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 92,776 shares of the company's stock after selling 192,593 shares during the period. Voya Investment Management LLC's holdings in Cencora were worth $27,856,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Deutsche Bank AG bought a new stake in Cencora in the second quarter worth $286,673,000. Wedge Capital Management L L P NC lifted its position in Cencora by 31.0% during the second quarter. Wedge Capital Management L L P NC now owns 105,614 shares of the company's stock valued at $29,887,000 after purchasing an additional 24,968 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in Cencora during the second quarter valued at $841,000. Peachtree Investment Partners LLC purchased a new position in shares of Cencora in the 2nd quarter worth $2,204,000. Finally, Summit Global Investments purchased a new position in shares of Cencora in the 2nd quarter worth $2,283,000. Hedge funds and other institutional investors own 97.52% of the company's stock.

Insider Activity

In related news, EVP Elizabeth Campbell sold 11,300 shares of the stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $324.12, for a total value of $3,662,556.00. Following the transaction, the executive vice president owned 19,455 shares of the company's stock, valued at $6,305,754.60. This represents a 36.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.38% of the company's stock.

Cencora Trading Down 0.6%

Shares of COR opened at $339.05 on Friday. The firm has a market capitalization of $64.70 billion, a price-to-earnings ratio of 18.92, a PEG ratio of 1.85 and a beta of 0.58. The company has a debt-to-equity ratio of 3.01, a current ratio of 0.94 and a quick ratio of 0.59. Cencora, Inc. has a 1-year low of $244.82 and a 1-year high of $377.54. The company has a 50-day moving average of $329.42 and a 200 day moving average of $316.95.

Cencora (NYSE:COR - Get Free Report) last issued its earnings results on Wednesday, November 4th. The company reported $4.66 EPS for the quarter, topping analysts' consensus estimates of $4.58 by $0.08. The business had revenue of $88.35 billion for the quarter, compared to the consensus estimate of $87.95 billion. Cencora had a net margin of 1.03% and a return on equity of 110.72%. The company's revenue for the quarter was up 5.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.84 EPS. On average, research analysts expect that Cencora, Inc. will post 19.58 EPS for the current year.

Cencora Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, November 30th. Investors of record on Friday, November 13th will be issued a $0.66 dividend. The ex-dividend date is Friday, November 13th. This is a positive change from Cencora's previous quarterly dividend of $0.60. This represents a $2.64 dividend on an annualized basis and a dividend yield of 0.8%. Cencora's dividend payout ratio (DPR) is presently 14.73%.

Analysts Set New Price Targets

COR has been the subject of a number of recent research reports. Robert W. Baird lifted their target price on Cencora from $373.00 to $375.00 and gave the stock an "outperform" rating in a report on Thursday, October 22nd. JPMorgan Chase & Co. boosted their price objective on shares of Cencora from $390.00 to $413.00 and gave the company an "overweight" rating in a research report on Tuesday, November 10th. UBS Group reduced their target price on shares of Cencora from $430.00 to $400.00 and set a "buy" rating on the stock in a research note on Friday, October 16th. Morgan Stanley raised their target price on shares of Cencora from $346.00 to $377.00 and gave the stock an "overweight" rating in a report on Friday, October 30th. Finally, Barclays lifted their price target on shares of Cencora from $350.00 to $415.00 and gave the stock an "overweight" rating in a research note on Wednesday. Thirteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $381.00.

View Our Latest Report on Cencora

About Cencora

(Free Report)

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical services company that connects pharmaceutical manufacturers with healthcare providers. Its core business includes sourcing and distributing medicines and other healthcare products to pharmacies, hospitals, health systems and other care providers. The company also provides services supporting specialty pharmaceuticals, including logistics, consulting and solutions for manufacturers and healthcare organizations. These services help manage the handling and delivery of complex medicines and support access to treatments.

Further Reading

Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR - Free Report).

Institutional Ownership by Quarter for Cencora (NYSE:COR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Cencora Right Now?

Before you consider Cencora, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.

While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines